Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient betahistine (excl. potency 6 mg and 12 mg) f. d. Z. October 1st, 2026 - September 30th, 2028 (plus V. option 1x12 months)
By: DAK HEALTH📍 GermanyOpen
Key Information
| Reference | GB-570684-2026 |
|---|
| Deadline | Aug 5, 2029 12:00 AM |
|---|
| Estimated Value | €1.00 |
|---|
| Competition Type | ICB |
|---|
| Funding Source | Self-Funded |
|---|
| Country | Germany |
|---|
| Address | City : Hamburg
Postal code : 20097
Telephone : +49 402364855-1194
Country : Germany |
|---|
| Published | Aug 18, 2026 |
|---|
Description
<br/>§ 130a Paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory...
Full details are available after unlocking this tender.